Akathisia: Definition and Treatment
Akathisia is a distressing movement disorder characterized by subjective inner restlessness and objective motor restlessness (body rocking, pacing, leg shuffling, fidgeting), most commonly induced by antipsychotic medications, and should be treated first by lowering the antipsychotic dose or switching to a lower-liability agent, followed by beta-blockers or benzodiazepines as add-on therapy if dose adjustment is not feasible 1.
What is Akathisia?
Akathisia manifests as:
- Subjective symptoms: Inner restlessness, inability to remain seated, restless legs, constant desire to move
- Objective signs: Body rocking, shifting foot-to-foot, stamping in place, crossing/uncrossing legs, pacing 2, 3
This syndrome affects up to 30% of patients on antipsychotics and is severely distressing, potentially leading to non-adherence and treatment complications 4.
Treatment Algorithm
Step 1: Modify the Antipsychotic (First-Line)
The most reliable treatment is reducing the antipsychotic dose or switching to an agent with lower akathisia liability 1, 5. The APA guidelines specifically suggest three options as equivalent first-line approaches 1:
- Lower the antipsychotic dosage
- Switch to another antipsychotic (preferably one with lower akathisia risk)
- Add pharmacological treatment (if dose reduction/switching not feasible)
Important caveat: Dose reduction or switching may not be possible if it risks worsening the underlying psychiatric condition 3. In acute psychosis management, this creates a clinical dilemma requiring careful risk-benefit assessment.
Step 2: Add Pharmacological Treatment (When Step 1 Not Feasible)
When antipsychotic modification is not possible, the evidence supports the following hierarchy:
First-Choice Add-On Agents:
Beta-blockers (specifically propranolol) have the strongest evidence base 1, 6, 4, 2, 5. The 2024 network meta-analysis found beta-blockers significantly improved akathisia severity (SMD -0.46), though with low confidence 6.
5-HT2A antagonists (mirtazapine, mianserin, cyproheptadine) showed the strongest effect size in the 2024 network meta-analysis (SMD -1.07) 6, and mirtazapine is specifically supported alongside propranolol as having the best current evidence 2.
Second-Choice Add-On Agents:
Benzodiazepines (particularly clonazepam) demonstrated very strong effect sizes (SMD -1.62) but with very low confidence in evidence 1, 6, 4. They ranked highest in one 2024 meta-analysis (P-score 0.8186) 4.
Third-Choice Options:
Anticholinergics (biperiden, trihexyphenidyl) are suggested by APA guidelines 1 and supported by systematic reviews 5, 3, though they showed no significant difference versus placebo in one 2024 network meta-analysis 4.
Vitamin B6 showed promising effects (SMD -0.99) but with very low confidence 6.
Clinical Pitfalls to Avoid
Don't ignore akathisia assessment: Systematically assess with validated scales before starting antipsychotics and during dose titration 5
Don't continue antipsychotic polypharmacy: Cessation of polypharmacy should be considered before adding adjuvant medications 5
Don't use adjuvant medications indefinitely: The evidence for long-term efficacy of add-on agents is absent, warranting cautious prescribing regarding duration 6, 5
Don't overlook contraindications: Beta-blockers have cardiovascular contraindications; anticholinergics can worsen cognition; benzodiazepines carry dependence risk 5
Recognize dose-response relationships: Most antipsychotics show increasing akathisia risk with higher doses (hyperbolic or monotonic curves), except sertindole and quetiapine which show flat curves 7
Evidence Quality Considerations
The 2020 APA guideline provides a 2C recommendation (suggestion with low confidence) for the treatment options, reflecting the limited quality of available evidence 1. The most recent 2024 network meta-analyses confirm this limitation, rating confidence as low to very low for most interventions 6. This reflects small sample sizes (only 661 total participants across 19 trials), short study durations, and absence of long-term efficacy data 6.
The practical implication: Given the low evidence quality but high clinical need, use beta-blockers or mirtazapine as first-choice add-on agents when antipsychotic modification is not feasible, with careful monitoring for side effects and consideration of time-limited trials rather than indefinite use.